The Novartis and Eli Lilly-backed cancer and haematologic disease drug developer will go public today having expanded the size of its offering.
US-based haematologic disease and cancer drug developer Forma Therapeutics priced a $278m initial public offering yesterday that will provide exits for pharmaceutical firms Eli Lilly and Novartis.
The offering comprises nearly 13.9 million shares priced at $20 each, above the IPO’s $16 to $18 range and increased from about 11.8 million shares. It will float on the Nasdaq Global Market later today and the IPO price values it at approximately $778m.
Forma is developing therapies to treat cancer and…
